DUBLIN, April 12, 2021 /PRNewswire/ -- Cosmo Pharmaceuticals NV (SIX: COPN) today announced the FDA approval of GI Genius™ intelligent endoscopy system, its revolutionary device for lesion detection ...

Dublin, Ireland--(Newsfile Corp. - September 2, 2024) - Cosmo Intelligent Medical Devices (Cosmo IMD), a division of Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”), the developer and ...

Agreement expands partnership between Medtronic and Cosmo Pharmaceuticals, set to transform endoscopy with cutting-edge AI technology DUBLIN, Dec. 11, 2023 /PRNewswire/ -- Medtronic plc (MDT) (NYSE: ...

Medtronic has entered a definitive agreement to expand its partnership with Cosmo Intelligent Medical Devices to further capitalize on the achievements of Medtronic’s GI Genius intelligent endoscopy ...

EQS Group-Ad-hoc: COSMO Pharmaceuticals N.V. / Key word(s): Regulatory Approval Cosmo announces regulatory approval of GI Genius(TM) in Canada 17-Nov-2021 / 06:00 GMT/BST Release of an ad hoc ...

Please provide your email address to receive an email when new articles are posted on . Medtronic recently received FDA de novo clearance for the GI Genius intelligence endoscopy module. GI Genius is ...

A strategic collaboration with Cosmo Pharmaceuticals and NVIDIA delivers the GI Genius™ AI Access™ platform designed to accelerate AI innovation for healthcare. DUBLIN, March 22, 2023 /PRNewswire/ -- ...

Medtronic plc has announced a plan by Cosmo Pharmaceuticals NV and Nvidia Inc. to integrate Nvidia's artificial intelligence (AI) technologies into Medtonic’s GI Genius intelligent endoscopy module.

Please provide your email address to receive an email when new articles are posted on . Mean number of adenomas per procedure was higher with GI Genius vs. standard colonoscopy (1.56 vs. 1.21), as was ...